Fate Therapeutics (FATE) Tops Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Fate Therapeutics Reports Second Quarter 2016 Financial Results
August 8, 2016 4:01 PM EDTOpened Patient Enrollment in Phase 1/2 Clinical Trial of ProTmune for Prevention of Acute GvHD and CMV Infection
IND Filing for Allogeneic Memory-Like NK Cell Cancer Immunotherapy Planned for 2016
Announced $10.3 Million Common Stock Private Placement
SAN DIEGO, Aug. 08, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today reported business highlights and financial results for the second quarter ended June 30, 2016.
With the opening of... More
